Elanco Companion Animal Health has launched of Dexdomitor 0.1 mg/ml, adding to its range of alpha-2 agonists and antagonists. 

Produced and manufactured in partnership with Orion Corporation, Elanco says Dexdomitor 0.1 mg/ml contains all the properties of dexmedetomidine in a formulation that allows accurate and convenient dosing for the smallest patients. It can be used as a sedative for non-invasive, mild to moderately painful procedures and examinations which require restraint, sedation and analgesia in dogs and cats.  It can also be used for deep sedation and analgesia in dogs in concomitant use with butorphanol for medical and minor surgical procedures and as a pre-medication in dogs and cats before induction and maintenance of general anaesthesia.

Dexdomitor 0.1 mg/ml has been designed to provide accurate dosing in very small dogs (up to 5kg) for sedation and pre-medication, small to mid-size dogs (up to 20kg) for pre-medication, and small cats (up to 3kg) for sedation and pre-medication.

Ed Whittle MRCVS, technical consultant at Elanco Companion Animal Health said: "With nearly a quarter of dogs weighing less than 6kg and nearly three-quarters weighing less than 23.1kg¹, Dexdomitor 0.1mg/ml is ideal for small animals that require low concentration doses of dexmedetomidine for convenient and accurate dosing".

Elanco has has also produced a sedation and pre-medication dosing guide to educate veterinary professionals on the recommended doses for its range of alpha-2 agonists and alpha-2 antagonists.

For further information contact your Elanco Companion Animal Health key account manager or email elancoCAH.uk@elanco.com.

PS: Whilst you're here, take a moment to see our latest job opportunities for vets.